/
Oncology
Soft Tissue Sarcoma
77
Pipeline Programs↗
88
Active Trials↗
58
Companies Involved↗
Soft Tissue Sarcoma is a moderately active landscape with 77 programs across 58 companies. The most active players are AstraZeneca, HRYZ Biotech Co.. 20 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 110
Phase 239
Phase 320
Approved
No programs
Analysis
Modality Breakdown
74%
Small molecule
54 of 73 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 73 classified programs, each share of the total. Modality classified for 97% of 77 pipeline programs.
Analysis
Trial Status
347
clinical trials
Completed162 · 47%
Recruiting50 · 14%
Unknown status49 · 14%
Terminated32 · 9%
Active, not recruiting25 · 7%
Not yet recruiting13 · 4%
Other16 · 5%
Clinical Trials
Trial Activity
347 trials
A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma
Recruiting·—·Preclinical·NCT06797999·270 enrolled
Page 1 of 24
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)